209 results on '"Downing, Nicholas S."'
Search Results
2. Urban–Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment–Elevation Myocardial Infarction in China From 2001 to 2011: A Retrospective Analysis From the China PEACE Study (Patient-Centered Evaluative Assessment of Cardiac Events)
3. Are non-ST-segment elevation myocardial infarctions missing in China?
4. Characteristics of Novel Therapeutics and Postmarket Safety Events—Reply
5. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014
6. Ischaemic heart disease in China: the time to address rising mortality rates
7. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study
8. Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study
9. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study
10. Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013
11. Market Exclusivity for Top-Selling Pharmaceuticals: Too Long, Too Short, or Just Right?
12. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
13. Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011: A Cross-sectional Study
14. Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis
15. Withdrawal of Personal Genome Service—Reply
16. Trial Evidence and Approval of Therapeutic Agents—Reply
17. Innovation, Risk, and Patient Empowerment: The FDA-Mandated Withdrawal of 23andMeʼs Personal Genome Service
18. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
19. Generic Competition in a Flawed System: Pill Them, Bill Them—Reply
20. Review of Novel Therapeutics by Three Regulatory Agencies
21. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
22. Avoidance of Generic Competition by Abbott Laboratoriesʼ Fenofibrate Franchise
23. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
24. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis
25. Complements from the Lung
26. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
27. Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia
28. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis
29. New and incremental FDA black box warnings from 2008 to 2015
30. Quality of Care in Chinese Hospitals: Processes and Outcomes After ST‐segment Elevation Myocardial Infarction
31. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study
32. Describing the performance of U.S. hospitals by applying big data analytics
33. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
34. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
35. Regulatory Review of New Therapeutic Agents — FDA versus EMA, 2011–2015
36. Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes
37. Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study
38. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005‐2014
39. Ischaemic heart disease in China: the time to address rising mortality rates
40. Analysis of Machine Learning Techniques for Heart Failure Readmissions
41. Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
42. China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction
43. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot
44. Qingdao Port Cardiovascular Health Study: a prospective cohort study
45. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study
46. Characterizing the US FDA's approach to promoting transformative innovation
47. 10 year trends in urban–rural disparities in treatments and outcomes after ST-elevation myocardial infarction in China: insights from the China PEACE-Retrospective Acute Myocardial Infarction Study
48. National assessment of statin therapy for patients with acute myocardial infarction, 2001–11: insight from the China PEACE-Retrospective Acute Myocardial Infarction study
49. Urban-Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment-Elevation Myocardial Infarction in China From 2001 to 2011: A Retrospective Analysis From the China PEACE Study (Patient-Centered Evaluative Assessment of Cardiac...
50. Organizational culture in cardiovascular care in Chinese hospitals: a descriptive cross-sectional study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.